WHO ICTRP trial
A GLOBAL, RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF REGN2810 (ANTI-PD-1 ANTIBODY)…
PER-038-17 · Registro Peruano de Ensayos Clínicos (REPEC) · Not Recruiting
Key facts
| Trial ID | PER-038-17 |
|---|---|
| Public title | A GLOBAL, RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF REGN2810 (ANTI-PD-1 ANTIBODY) VERSUS PLATINUM-BASED CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC PD-L1 + NON-SMALL CELL LUNG CANCER |
| Scientific title | A GLOBAL, RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF REGN2810 (ANTI-PD-1 ANTIBODY) VERSUS PLATINUM-BASED CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC PD-L1 + NON-SMALL CELL LUNG CANCER |
| Primary sponsor | Regeneron Pharmaceuticals Inc, |
| Registry | Registro Peruano de Ensayos Clínicos (REPEC) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | III |
| Countries | Philippines;Japan;Malasya;Thailand;Taiwan;Turkey;Spain;Greece;Poland;Portugal;Romania;Russian Federation;Ukraine;Australia;Czech Republic;Brazil;Chile;Colombia;Mexico |
| Conditions | -C349 Bronchus or lung, unspecified Bronchus or lung, unspecified;C349;Bronchus or lung, unspecified |
| Interventions | Group name:Group 1: REGN2810 Type of group;1 N° of participants:150 Intervention(s) description:REGN2810 (50mg / ml), administration of 350mg by IV infusion of 30 minutes on the 1st day of each 3-week cycle (Q3W) for a period of 108 weeks… |
| Registration date | May 25, 2018 |
| Target size | 72 |
| Secondary IDs | NCT03088540;2016-004407-31 |
| Registry page | ins.gob.pe |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: